Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
For InMed Pharmaceuticals, Inc., an amended beneficial-ownership report by ADAR1 Capital Management, LLC and Daniel Schneeberger states that private investment funds managed by ADAR1 directly own 943,668 common shares; those shares may be deemed indirectly beneficially owned by ADAR1 and its sole manager, Daniel Schneeberger. Both reporting persons reported shared voting and dispositive power over the position, with no sole voting or dispositive power. The reported ownership percentage is 17.2%, based on 5,493,735 common shares outstanding as of September 2, 2026.
Key Figures
Beneficially owned:943,668 common sharesPercentage of class:17.2%Common shares outstanding:5,493,735 shares+1 more
4 metrics
Beneficially owned943,668 common sharesThe same fund-held position is reported by ADAR1 Capital Management and Daniel Schneeberger.
Percentage of class17.2%Reported beneficial ownership percentage.
Common shares outstanding5,493,735 sharesAs of September 2, 2026; basis for the reported ownership percentage.
Sole voting and dispositive power0 sharesReported by each reporting person.
Key Terms
beneficially owned, Shared Voting Power, Shared Dispositive Power
3 terms
beneficially ownedregulatory
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Powerregulatory
"Shared Voting Power 943,668.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Powerregulatory
"Shared Dispositive Power 943,668.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many INM shares do ADAR1 Capital Management and Daniel Schneeberger report?
ADAR1 Capital Management, LLC and Daniel Schneeberger each report beneficial ownership of 943,668 common shares. The shares are directly owned by private investment funds managed by ADAR1, and the reported position may be deemed indirectly beneficially owned by both reporting persons.
What percentage of INM does ADAR1 report owning?
The reported beneficial ownership is 17.2% of InMed's common shares. The percentage is based on 5,493,735 common shares outstanding as of September 2, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
InMed Pharmaceuticals, Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
457637700
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
457637700
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
943,668.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
943,668.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
943,668.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.2 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 943,668 shares of common shares, no par value ("Common Shares"), of InMed Pharmaceuticals, Inc. (the "Company") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 5,493,735 shares of Common Shares outstanding as of September 2, 2026, as reported in the Company's Annual Report on Form 10-K for the year ended June 30, 2026, filed with the Securities and Exchange Commission on September 9, 2026.
SCHEDULE 13G
CUSIP Number(s):
457637700
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
943,668.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
943,668.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
943,668.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.2 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 943,668 shares of common shares, no par value ("Common Shares"), of InMed Pharmaceuticals, Inc. (the "Company") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
The percentage in box 11 is based on 5,493,735 shares of Common Shares outstanding as of September 2, 2026, as reported in the Company's Annual Report on Form 10-K for the year ended June 30, 2026, filed with the Securities and Exchange Commission on September 9, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
InMed Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
Suite 1800 - 500 West Georgia St. Vancouver, A1 V6B 0M3
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and
(ii) Daniel Schneeberger ("Mr. Schneeberger").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company; and
(ii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP No.:
457637700
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
